Yubo International Biotech Ltd. (YBGJ) intrinsic value & 10-year financials
Yubo International Biotech Ltd. (YBGJ) has a Graham intrinsic value of $1.11 per share. At $0.01 on Oct 17, 2026, the stock trades 99% below that value. Over the last 10 fiscal years revenue shrank 68.4% a year to $12.4K, with an average return on invested capital of -57.3%.
- Graham intrinsic value
- $1.11
- Share price (Oct 17, 2026)
- $0.01
- Price vs Graham value
- 99% below
- Market cap
- $726.2K
- Revenue (FY2025)
- $12.4K
- Revenue growth (10-yr CAGR)
- -68.4%
- ROIC (10-yr avg)
- -57.3%
- Free cash flow (FY2025)
- —
YBGJ 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $12.4K | -$1.1M | -$0.01 | — | -9614.6% | 45.0% |
| FY2024 | $3.5K | -$2.0M | -$0.02 | — | -51006.3% | 70.0% |
| FY2023 | $604.7K | -$1.2M | -$0.01 | — | -197.6% | 124.0% |
| FY2022 | $104.3K | -$1.2M | — | $68.2K | -1155.7% | -582.6% |
| FY2021 | $1.2M | -$1.5M | — | -$1.6M | -124.0% | -254.2% |
| FY2020 | $0 | -$134.0K | — | — | — | 1.7% |
| FY2019 | $0 | -$148.0K | — | — | — | 3.0% |
| FY2018 | $0 | -$144.0K | — | — | — | 4.0% |
| FY2017 | $0 | -$224.0K | — | — | — | 11.3% |
| FY2016 | $0 | -$130.0K | — | — | — | 5.0% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Yubo International Biotech Ltd revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Yubo International Biotech Ltd has earned high returns on invested capital, averaging 25.6% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
Yubo International Biotech Ltd capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Yubo International Biotech Ltd is modeled at -68.4% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $1.11 per share.